Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent 'type I' mode

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Gillissen, B ^a   Richter, A ^a   Overkamp, T ^a   Essmann, F ^b   Hemmati, P G ^a   Preissner, R ^a   Belka, C ^c   Daniel, P T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Apoptosis; Bak; Bax; SMAC; TRAIL; XIAP

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 8; CYTOCHROME C; ENZYME ACTIVATOR; LBW 242; MITHRAMYCIN; PROCASPASE 3; PROTEIN BAK; PROTEIN BAX; PROTEIN BID; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL DEATH; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME DEGRADATION; GENE SILENCING; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; CASPASE 3; CASPASE 8; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HCT116 CELLS; HUMANS; OLIGOPEPTIDES; PLICAMYCIN; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

PYRONIA TITHONUS;

EID: 84879384319     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.67     Document Type: Article

References (41)

1. Gonzalvez F, Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010; 29: 4752-4765.
2. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002; 8: 3734-3740.
3. Schmelz K, Wieder T, Tamm I, Muller A, Essmann F, Geilen CC et al. Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB. Oncogene 2004; 23: 6743-6759.
4. Marini P, Schmid A, Jendrossek V, Faltin H, Daniel PT, Budach W et al. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer 2005; 5: 5.
5. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-1687.
6. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
7. van Delft MF, Huang DC. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 2006; 16: 203-213.
8. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE etal. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000; 102: 43-53.
9. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
10. Deveraux QL, Reed JC. IAP family proteins-suppressors of apoptosis. Genes Dev 1999; 13: 239-252.
11. LaCasse EC, Mahoney DJ, Cheung HH, Plenchette S, Baird S, KornelukRG. IAP-targeted therapies for cancer. Oncogene 2008; 27: 6252-6275.
12. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P etal. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 2002; 8: 274-281.
13. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ etal. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64: 3517-3524.
14. Gillissen B, Wendt J, Richter A, Richter A, Muer A, Overkamp T etal. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 2010; 188: 851-862.
15. Gillissen B, Essmann F, Hemmati PG, Richter A, Richter A, Oztop I et al. Mcl-1 determines the Bax dependency of Nbk/Bik-induced apoptosis. J Cell Biol 2007; 179: 701-715.
16. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290: 989-992.
17. Subramanian T, Chinnadurai G. Pro-apoptotic activity of transiently expressed BCL-2 occurs independent of BAX and BAK. J Cell Biochem 2003; 89:1102-1114.
18. Hornle M, Peters N, Thayaparasingham B, Vorsmann H, Kashkar H, Kulms D. Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis. Oncogene 2010; 30: 575-587.
19. Lee TJ, Jung EM, Lee JT, Kim S, Park JW, Choi KS etal. Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther 2006; 5: 2737-2746.
20. Keane MM, Rubinstein Y, Cuello M, Ettenberg SA, Banerjee P, Nau MM etal. Inhibition of NF-kappaB activity enhances TRAIL mediated apoptosis in breast cancer cell lines. Breast Cancer Res Treat 2000; 64: 211-219.
21. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP etal. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2009; 284:11121-11133.
22. InoueS, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class I is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2006; 66: 6785-6792.
23. Ricci MS, KimSH, Ogi K, PlastarasJP, Ling J, Wang Wetal. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007; 12: 66-80.
24. Ortiz-Ferron G, Yerbes R, Eramo A, Lopez-Perez AI, De Maria R, Lopez-Rivas A. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Cell Res 2008; 18: 664-676.
25. Huang S, Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008; 68: 2944-2951.
26. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004; 5: 25-35.
27. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M etal. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009; 69: 2425-2434.
28. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC etal. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009; 460:1035-1039.
29. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and-deficient cells. Oncogene 2004; 23: 2554-2558.
30. Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res 2010; 8: 729-738.
31. Liu FT, Agrawal SG, Gribben JG, Ye H, Du MQ, Newland AC et al. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood 2008; 111: 2797-2805.
32. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 2005; 4: 443-449.
33. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J1999; 18: 5242-5251.
34. Hundsdoerfer P, Dietrich I, Schmelz K, Eckert C, Henze G. XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL. Pediatr Blood Cancer 2010; 55: 260-266.
35. Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood 2007; 109:1220-1227.
36. Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S etal. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 1999; 17:1364-1374.
37. Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 2000; 60: 4328-4330.
38. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 1996; 56: 2422-2427.
39. MrozekA, Petrowsky H, Sturm I, Kraus J, HermannS, HauptmannS et al. Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. Cell Death Differ 2003; 10: 461-467.
40. Plötz M, Gillissen B, Hossini AM, Daniel PT, Eberle J. Disruption of the VDAC2-Bak interaction by Bcl-x(S) mediates efficient induction of apoptosis in melanoma cells. Cell Death Differ 2012; 19:1928-1938.
41. von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dorken B, Daniel PT. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop. Oncogene 2003; 22: 2236-2247.